Production of L-Ribose and Rare Sugars

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$101,675.00
Award Year:
2005
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI065127-01
Award Id:
75907
Agency Tracking Number:
AI065127
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Zuchem, Inc., 2201 W Campbell Park Dr, Ste 215, Chicago, IL, 60612
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
NATHAN WYMER
(309) 681-6188
WYMERN@ZUCHEM.COM
Business Contact:
GINA BERARDESCO
(312) 997-2150
ginab@zuchem.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Starting materials based on rare sugars that are used in the production of carbohydrate-based drugs are in low supply, therefore creating high prices. One such carbohydrate is L-ribose. L-Ribose is used in many different applications, including several nucleoside-based Pharmaceuticals presently available or undergoing clinical trials. As the need for these drugs increases, demand for L-ribose is going to increase significantly. This proposal outlines a new synthetic route to L-ribose production, which will result in lower-cost of manufacture than the current state-of-the-art. The technologies developed for the L-ribose production can then be translated into the production of other rare sugars to expand the portfolio of carbohydrate starting materials available to biochemists and synthetic carbohydrate chemists. The proposed route to L-ribose utilizes an enzymatic process. To achieve large-scale production of L-ribose a eukaryotic gene will be synthetically constructed to express in a microbial host. Initially, Escherichia coli and Saccharomyces cerevisiae will be tested as a suitable production system. This synthetic route has several potential advantages over the current commercial routes by using a single-step fermentation from a readily available starting material. Phase I of this proposal would study the gene expression within a heterologous expression strain. The goal of the phase I portion of the proposal is to produce an active gene within an expression host and improve the activity with directed evolution. The specific aims of this Phase I grant are 1) to construct and express the specific gene; 2) Assay development; and 3) Preliminary engineering of enzyme activity. By developing this advanced production of rare sugars used by the pharmaceutical industry and other research institutions, the public will have access to better and cheaper treatments for disease.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government